In research that could ultimately lead to many new medicines, scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed a potentially general approach to design drugs from genome sequence. As a proof of ...
Tags: Identify New Drug Candidates, unparalleled selectivity, cell permeable
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx") announced that it has received Orphan Drug designation from U.S. FDA's Office of Orphan Products Development (OOPD) for its drug candidate, Thymosin beta 4 ...
Tags: RegeneRx Biopharmaceuticals, Orphan Drug designation, Thymosin beta 4
NanoViricides has received results of detailed lab analysis studies from the initial non-GLP toxicology studies of intravenously administered FluCide. No overt adverse safety and toxicology effects were observed in this study of the ...
Taiwan-based JHL Biotech and Switzerland-based Selexis have formed a biologic drug development alliance to serve the biopharmaceutical industry. JHL Biotech and Selexis have signed a non-exclusive strategic agreement to provide seamless ...
Tags: Health, Medicine, taiwan, Biologic Drug
The US Food and Drug Administration (FDA) has granted orphan drug designation to Conatus Pharmaceuticals' drug candidate emricasan for the treatment of liver transplant patients with reestablished fibrosis to delay the progression to ...
Canada-based ImStar Therapeutics has announced the selection of IMS-088 as its lead drug candidate for the treatment of amyotrophic lateral sclerosis. IMS-088 is a novel, small-molecule drug that stems from the discovery of a new target ...
Viteava Pharmaceuticals has announced the execution of an exclusive worldwide license to an intellectual property portfolio claiming composition of matter and/or methods of use of novel analogs and derivatives of the green tea flavonoid, ...
Tags: exclusive worldwide license, EGCG, Viteava Pharmaceuticals
Signum Dermalogix, a biopharmaceutical company, has announced that the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded the company a Small Business Innovation Research (SBIR) Phase II grant totaling ...
NanoViricides has secured orphan drug designation from the European Medicines Agency (EMA) for its drug candidate DengueCide, for the treatment of dengue and dengue hemorrhagic fever. Dengue fever is a mosquito-borne disease that affects ...
Tags: Nanoviricides Drug
Cancer Research UK's commercial arm Cancer Research Technology (CRT) has collaborated with Danish drug discovery firm Nuevolution for the discovery of anti-cancer drug molecules targeting several key proteins. The deal is aimed at ...
Tags: Cancer Drugs, Medicine
Synta Pharmaceuticals has announced the publication of the company's first patent application covering its proprietary Hsp90-inhibitor drug conjugate (HDC) platform, which leverages the company's expertise in chaperone biology and medicinal ...
Alzheon announced the launch of the company, the securing of initial private financing, and the signing of an exclusive license agreement to a novel clinical drug candidate for Alzheimer’s disease, a family of analogs, and a drug ...
Tags: Alzheon, Alzheimer's Disease
Senesco Technologies reported the treatment of the first patient at the Company’s newly opened clinical-trial site at Seattle Cancer Care Alliance (SCCA). This patient is part of Senesco’s Phase 1b/2a clinical study of its ...
Tags: Senesco, Clinical Trial
US-based pharmaceutical firm Merck has received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for its investigational oral combination regimen MK-5172/MK-8742 for the treatment of chronic hepatitis C virus ...
Danish biotechnology firm Genmab has unveiled positive results from a Phase II study of its sclerosis drug candidate ofatumumab in relapsing-remitting multiple sclerosis (RRMS). In a randomized study of 232 patients with RRMS, treatment ...
Tags: Genmab, Sclerosis Drug